Enzo Biochem, Inc. (NYSE: ENZ) today announced that its Enzo Clinical
Labs subsidiary has strengthened its senior management team with the
appointment of Kevin Krenitsky, M.D., as President. Krenitsky is a
highly respected 12-year veteran of the life sciences industry, bringing
a wealth of experience in building and managing global diagnostic
operations.
"Kevin’s impressive credentials in the clinical service, molecular
diagnostics, and pre-clinical and clinical pharma, should serve us well
as we continue to develop Enzo Clinical Labs into a molecular and
esoteric center of excellence,” said Barry Weiner, President of Enzo
Biochem, Inc. "Kevin’s extensive operational experience along with his
success in the launching of new service offerings will be instrumental
in growing Enzo Clinical Labs.”
Prior to joining Enzo Clinical Labs, Dr. Krenitsky, who is replacing
Shahram Rabbani, was Chief Executive Officer of Bioserve Biotechnologies
Ltd, a global biotech company that validates, processes, and develops
molecular diagnostics. Prior to Bioserve, he was Chief Executive Officer
of Parkway Clinical Laboratories, a clinical diagnostic lab providing
comprehensive routine and esoteric testing. He previously served as
Senior Vice President and Division Head at SeraCare Life Sciences’
Genomics Collaborative Division (GCI), where he managed all worldwide
diagnostic and pharmaceutical R&D collaborations. Before GCI was
acquired by Seracare Life Sciences, Dr. Krenitsky acted as the company’s
Medical Director, responsible for spearheading the development of GCI’s
global network of five hundred-plus clinical sites on four continents.
During his tenure at GCI, Dr. Krenitsky was instrumental in developing
several hundred agreements with dozens of major pharmaceutical,
biotechnology, and diagnostic companies worldwide.
Dr Krenitsky received his M.D. from Jefferson Medical College.
About Enzo
Enzo Biochem is engaged in the research, development, manufacture and
licensing of innovative health care products and technologies based on
molecular biology and genetic engineering techniques, and in providing
diagnostic services to the medical community. Enzo’s Life Sciences
division develops, produces and markets proprietary labeling and
detection products for gene sequencing, genetic analysis and
immunological research among others. Its catalog of over 33,000
products serves the molecular biology, drug discovery and pathology
research markets. The Company's therapeutic division is in various
stages of clinical evaluation of its proprietary immune regulation
medicines for uveitis and Crohn's Disease and conducts pre-clinical
research on several candidate compounds aimed at producing new mineral
and organic bone, including technology that could provide therapy for
osteoporosis and fractures, among other applications. Enzo’s Clinical
Labs division provides routine and esoteric reference laboratory
services for physicians in the New York Metropolitan and New Jersey
areas. Underpinning the Company’s technology and operations is an
extensive intellectual property estate in which Enzo owns or licenses
over 230 patents worldwide, and has pending applications for over 200
more. For more information visit our website www.enzo.com.
Except for historical information, the matters discussed in this news
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that could
materially affect actual results. The Company disclaims any obligations
to update any forward-looking statement as a result of developments
occurring after the date of this press release.
